Fintel on MSN12h
TD Cowen Upgrades Salesforce (CRM)
Fintel reports that on January 17, 2025, TD Cowen upgraded their outlook for Salesforce (NYSE:CRM) from Hold to Buy. Analyst ...
Odyssey Therapeutics Files for IPO
The company said Friday it develops medicines designed to precisely target disease pathology with an initial emphasis on the innate immune system. Odyssey said its most advanced programs include ...
Stereotaxis Positioned for 2025 Growth: Buy Rating Backed by Strong Pipeline, Regulatory Approvals, and Solid Financials
Analyst Josh Jennings of TD Cowen reiterated a Buy rating on Stereotaxis (STXS – Research Report), retaining the price target of $5.00.Stay ...
TD Cowen lifts O'Reilly stock target to $1,400, maintains Buy rating
TD Cowen analysts, led by Max Rakhlenko, increased their price target on O'Reilly Automotive (NASDAQ:ORLY) shares to $1,400 ...
Positive Growth Outlook for SLM Amid Competitor’s Exit and Regulatory Tailwinds
Jefferies analyst John Hecht reiterated a Buy rating on SLM (SLM – Research Report) today and set a price target of $33.00.Stay Ahead of the ...